ArticleFoods (Basel, Switzerland)2026
Ameliorative Effects of Pumpkin Seed Protein Peptides on Dexamethasone-Treated Sarcopenia and Their Effects When Combined with Vitamin D.
Article in Foods (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Sarcopenia is a degenerative condition that imposes a substantial global public health burden, yet safe and effective interventions remain limited. Nutritional support is regarded as an important strategy to mitigate age-related muscle loss and improve physical function in older adults. Due to time and cost constraints, dexamethasone (DEX)-treated models are often used as an alternative to age-related sarcopenia models. This study investigated the effects of pumpkin seed protein peptides (PSPP) and vitamin D on DEX-treated mice. In vitro, PSPP attenuated senescence-associated phenotypes, reduced cellular injury, and partially alleviated DEX-treated myofibrillar atrophy, as evidenced by decreased Atrogin-1 and MuRF1 expression and increased MyoD expression. In vivo, PSPP and vitamin D, particularly in combination, ameliorated DEX-treated declines in muscle mass, grip strength, and endurance. Histological analyses further demonstrated improvements in myofibrillar architecture and muscle fiber cross-sectional area. In addition, each intervention was associated with increased ATP content, elevated interleukin-10 and insulin-like growth factor-1 levels, and reduced tumor necrosis factor-α and malondialdehyde levels. Collectively, these findings suggest that PSPP, either alone or combined with vitamin D, may alleviate DEX-treated sarcopenia, potentially through the modulation of mitochondrial homeostasis, attenuation of oxidative stress and inflammatory responses, and promotion of myogenic regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.